NetworkNewsBreaks – Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) Featured in Channelchek Research Report, Releases Q1 2020 Financial Results
Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) was featured in an April Research Report published by Channelchek. The report, titled, “Two Breakthrough Medical Technologies for Cardiovascular Markets,” details two Neovasc products, including Tiara for the transcatheter treatment of mitral valve disease and the Neovasc Reducer for the treatment of refractory angina. The report reads, “Neovasc is seeking FDA approval to commercialize the Reducer for the treatment of refractory angina in the United States. Patients suffering from refractory angina, a debilitating disease characterized by chronic chest pain, do not have any effective therapeutic options. The Reducer, commercially available in Europe, but not…